Gyki 14,451, a Synthetic Tripeptide Inhibitor of Thrombin: “In Vitro” and “In Vivo” Studies
The search for new compounds active in blood coagulation with different properties to classical anticoagulants, e.g. heparin, has led in the recent years to the development of synthetic low molecular weight peptides, inhibitors of the clotting enzymes (1,2). Among these compounds the benzamidine derivatives and the peptidylarginals have been extensively studied in vitro and in vivo blood coagulation. The effects of a synthetic tripeptide, GYKI 14,451 (Boc-D-Phe-Pro-Arg-H) have been studied in our Laboratory both in vitro on platelets and blood coagulation and in vivo in the experimental animal.
KeywordsBlood Coagulation Platelet Rich Plasma Partial Thromboplastin Time Thrombin Time Caudal Vein
Unable to display preview. Download preview PDF.
- 1.F. Markwardt, Pharmacological control of blood coagulation by synthetic low molecular weight inhibitors of clotting enzymes. Trends Pharmacol. Sci. 1(6):153 (1980).Google Scholar